Willingness to pay for antihypertensive care: evidence from a staff-model HMO

Willingness to pay (WTP) has been used in Sweden to evaluate the value of antihypertensive therapy. The Swedish studies indicate that hypertensive patients are willing to pay between $107 and $120 per month for their therapy. We conducted a similar study in a population of hypertensive patients in a large, staff-model, managed care organization (Group Health Cooperative of Puget Sound). Participants returned a postal survey containing a WTP question with 10 "bids" ranging from $25 to $250. Respondents recorded whether they would accept or reject each bid at the stated dollar value. Demographic information such as age, income, and perceived health status was also collected. Results were analyzed with ordinary least squares regression, controlling for the demographic data. The estimated parameters were significant and indicated an adjusted mean WTP of $93 per month for antihypertensive therapy. The close similarity of the Swedish and U.S. results appears to support the use of WTP as a measure of health state preferences.